Hormone-Sensitive Prostate Cancer
Hormone-sensitive prostate cancer (HSPC) is a type of prostate cancer that relies on androgens (male hormones) for growth and progression. It typically responds to therapies that reduce androgen levels or block their action, such as androgen deprivation therapy (ADT), making it a key target for treatment in early-stage disease. This form of cancer is also known as androgen-dependent, androgen-sensitive, or castrate-sensitive prostate cancer (CSPC).
References:
-
Hormone-Sensitive Prostate Cancer (1)
SCH-451659
Cat. No.: HY-118382
CAS No.: 502628-66-2
Synonyms: STX1383
- Formula: C30H39Cl2N3O2
- Molecular Weight: 544.56
SCH-451659 (STX1383) is an orally active, selective 17β-HSD3 inhibitor with an IC50 of 2.4 nM against h17β-HSD3. SCH-451659 selectively blocks the conversion of androstenedione to testosterone. SCH-451659 reduces testosterone levels in mice. SCH-451659 exhibits anticancer activity against androstenedione-dependent prostate tumors.
